Description
Disclaimer: This compound is provided strictly for laboratory and scientific research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use, including ingestion, injection, or any form of administration.
Compound Overview
MK-777 (Acetamoren) represents a non-peptide spiropiperidine derivative investigated as a potential growth hormone secretagogue receptor (GHS-R1a) ligand. This compound shares structural features with ibutamoren (MK-677) but differs in molecular composition through acetyl group substitution, placing it within the broader non-peptide ghrelin receptor agonist chemical class under preclinical evaluation.
No peer-reviewed publications specific to MK-777 exist as of 2026. All investigational applications discussed are extrapolated from the documented pharmacology of structurally related spiropiperidine GHS-R1a agonists and should be considered hypothetical until experimental validation is completed.
MK-777 is classified as a ghrelin receptor ligand candidate, not a selective androgen receptor modulator. MK-777 is not approved by the FDA for human or veterinary use and is intended strictly for institutional laboratory research purposes.
Chemical Properties of the Compound
| Property | Details |
| Compound Class | Growth Hormone Secretagogue Receptor Ligand (Non-Peptide) |
| CAS Number | 950841-87-9 |
| Molar Mass | 570.7 g/mol |
| Chemical Formula | C₂₉H₃₈N₄O₆S |
| PubChem CID | Not available |
| IUPAC Name | Not available (compound not listed in PubChem database) |
| Synonyms | Acetamoren, MK777, MK 777 |
| Physical Form | Available in three research formats: Liquid solution (30 mL bottle, 1,000 mg total, 33 mg/mL concentration); Tablet form (20 mg per tablet, available as 27-tablet supply [540 mg total] or 54-tablet supply [1,080 mg total]); Capsule form (20 mg per capsule, 50-capsule supply [1,000 mg total]) |
| Solubility | Soluble in DMSO; limited aqueous solubility |
| Purity Percentage | ≥98% purity by HPLC analysis |
| Stability / Shelf Life | Stable under controlled laboratory conditions; degradation may occur with exposure to heat, light, or moisture |
| Storage Instructions | Tablet / Capsule: Keep tightly sealed at room temperature, away from light, heat, and moisture.
Liquid: Keep tightly sealed under refrigeration (2°C–8°C), away from light, heat, and moisture. |
| Classification | Research Use Only (RUO) |
Chemistry Note for Researchers: MK-777 is not listed in PubChem. Chemical data derives from ChemicalBook CAS 950841-87-9. Structural variation exists across vendor specifications. BC9 provides batch-specific Certificate of Analysis confirming molecular identity per lot.
Institutional Research Compliance Framework
BC9 provides MK-777 Acetamoren specifically for institutional research applications. All purchases must comply with applicable institutional review and animal care framework requirements.
Institutional Review Board (IRB) Considerations
- Any human-subject research involving compound-related protocols requires IRB approval before initiation
- BC9 does not supply MK-777 for human research applications under any circumstance
- Institutional research compliance officers should verify protocol approval before procurement
Institutional Animal Care and Use Committee (IACUC) Framework
- Preclinical animal research involving MK-777 requires IACUC approval per the Animal Welfare Act (AWA)
- Standard preclinical protocols include controlled dosing, monitoring procedures, and ethical review documentation
- BC9 supplies for IACUC-approved research programs only
Regulatory Documentation Available
- Certificate of Analysis (COA) per production batch
- Safety Data Sheet (SDS) available upon institutional request
- Material handling documentation
- Institutional purchase order documentation support
- Laboratory record-keeping format support
- Batch traceability for research reproducibility
Enhanced Regulatory Notice — Growth Hormone Secretagogue Class
Compounds that interact with growth hormone secretagogue receptors carry significantly elevated regulatory exposure. Growth hormone is controlled under the Anti-Drug Abuse Act of 1988 and may only be distributed with valid prescription. MK-777 is supplied strictly for in vitro bioassay and preclinical model research only. Unauthorized human use or distribution may violate federal law.
For Research Compliance Officers
BC9 maintains documentation supporting institutional purchasing processes for research compound procurement. Verification documentation is available to research compliance teams as needed for grant management and institutional reporting requirements.
Working Mechanism of MK-777 Acetamoren
Research Transparency: No published data exists for MK-777. The following reflects potential investigational areas based on structural similarity to characterized spiropiperidine GHS-R1a agonists.
GHS-R1a Binding Characterization
MK-777 is investigated in receptor binding assays as a spiropiperidine-class GHS-R1a ligand. Structural analogs in this class have demonstrated selective growth hormone release activity through ghrelin receptor activation, establishing context for comparative binding studies. Receptor affinity and functional efficacy remain uncharacterized for MK-777.
Growth Hormone Axis Modulation
If functional activity is demonstrated, MK-777 may be investigated for somatotropic axis effects. Studies of structurally related compounds have documented sustained GH and IGF-1 elevation in elderly populations, representing potential investigational frameworks for spiropiperidine derivatives.
Metabolic Parameter Investigation
Ghrelin receptor agonists have shown effects on body composition including fat-free mass changes and energy expenditure modulation. These observations provide context for metabolic research applications if MK-777 demonstrates GHS-R1a activity.
Research Findings and Research Applications
Critical Limitation: No MK-777-specific data exists. Applications listed are hypothetical based on chemical class similarity.
Potential investigational areas include in vitro GHS-R1a binding assay development, structure-activity relationship characterization within the spiropiperidine series, receptor selectivity profiling in transfected cell systems, and analytical method development for non-peptide secretagogue detection.
If receptor activity is confirmed, investigations may extend to neuroendocrine pathway characterization and sleep architecture modulation, consistent with documented effects of structurally related GHS-R1a agonists.
Note: All research applications listed above are hypothetical and based on structural analogy. No published data confirms any biological activity for MK-777. Researchers should treat this compound as an uncharacterized chemical entity requiring de novo pharmacological evaluation.
Risk & Handling
PPE Requirements: The use of appropriate personal protective equipment is essential when conducting research with MK-777. Required PPE includes nitrile gloves, lab coat, and eye protection at minimum.
Laboratory Environment: Handling should occur within controlled laboratory environments specifically designed for research activities, with appropriate ventilation and biosafety measures.
Exposure Precautions: Do not inhale, ingest, or make direct skin contact with the compound. Avoid inhalation of powder during weighing procedures. For liquid formulations, avoid skin contact and accidental ingestion.
Toxicological Profile: The toxicological profile is not established for MK-777. Exposure risks remain completely uncertain due to absence of any published safety data. No human safety data has been established for this research-grade formulation.
Storage and Stability: Improper storage conditions, including exposure to heat, light, or moisture, may compromise compound stability and sample integrity. Tablet/Capsule: Store in sealed containers at room temperature. Liquid: Store refrigerated at 2°C–8°C in sealed containers.
For queries, complaints, or support, please contact support@bc9.co
Frequently Asked Questions
How does MK-777 differ from MK-677?
MK-777 contains an acetyl substitution (C₂₉H₃₈N₄O₆S) versus MK-677’s structure (C₂₇H₃₆N₄O₅S). Both belong to the spiropiperidine GHS-R1a agonist class but are distinct chemical entities. MK-777 lacks published characterization.
What formats are available?
Liquid (30 mL, 33 mg/mL), tablets (20 mg, 27 or 54 count), capsules (20 mg, 50 count).
What research exists on MK-777?
None. No peer-reviewed publications specific to MK-777 exist as of 2026. All mechanistic discussion extrapolates from MK-677 and related spiropiperidine pharmacology.
Is MK-777 a SARM?
No. MK-777 is a ghrelin receptor ligand candidate, not an androgen receptor modulator.
References
Transparency Note: References below pertain to MK-677 (ibutamoren) and the spiropiperidine GHS-R1a agonist class. No MK-777-specific publications exist.
- Bowers, C.Y., Momany, F., Reynolds, G.A., Chang, D., Hong, A., & Chang, K. (1995). Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology, 114(5), 1537-1545. https://pubmed.ncbi.nlm.nih.gov/7624358/
- Chapman, I.M., Bach, M.A., Van Cauter, E., et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249-4257. https://doi.org/10.1210/jcem.81.12.8954023
- Svensson, J., Lönn, L., Jansson, J.O., et al. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2), 362-369. https://doi.org/10.1210/jcem.83.2.4539
- Copinschi, G., Leproult, R., Van Onderbergen, A., et al. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 66(4), 278-286. https://doi.org/10.1159/000127249
This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.
Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).
Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.
Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at support@bc9.co
IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.
ENHANCED REGULATORY NOTICE: Growth hormone is controlled under the Anti-Drug Abuse Act of 1988. Compounds that stimulate endogenous growth hormone release carry significantly elevated regulatory exposure and are supplied strictly for in vitro bioassay and preclinical model research only. Unauthorized human use or distribution may violate federal law. Purchaser assumes all liability for federal and state law compliance.
Reviews
There are no reviews yet